Table 1 Baseline characteristics of the SIPFR
Variable | Total, n | Value |
|---|---|---|
Age, years, at enrolment into the registry | 662 | 72.7 (68.0–78.0) |
Age, years, at diagnosis | 651 | 72.0(67.0–77.0) |
The time from IPF diagnosis to enrolment, months | 651 | 2 (0–15) |
Gender (male, n, %) | 662 | 490 (74.0) |
Basis of diagnosis | 662 | |
Multidiscipline conference (MDC) diagnosis | 275 (41.5) | |
Clinic radiological | 587 (88.7) | |
Thoracoscopic biopsy | 38 (5.7) | |
Open lung biopsy | 31 (4.1) | |
UIP status (confirmed and possible UIP, n, %) | 662 | 434 (65.5) |
Incident IPF, (n, %) | 662 | 422 (64.8) |
Exposure | 662 | 208 (31.4) |
Smoking history (yes, n, %) | 662 | 429 (64.8) |
Ex-smokers | 405 (61.2) | |
Current-smokers | 24 (3.6%) | |
BMI | 595 | 26.6 (24.2–29.4) |
Underweight (< 18.5 kg·m2, %) | 5 (0.8) | |
Normal weight (≥ 18.5– ≤ 25 kg·m2, %) | 196 (29.6) | |
Overweight (> 25– ≤ 30 kg·m2, %) | 266 (40.2) | |
Obesity (> 30 kg·m2, %) | 128 (19.3) | |
Physiology* | ||
FEV1, % predicted | 540 | 78.0 (66.0–90.0) |
FVC, % predicted | 507 | 71.0 (61.0–85.0) |
FEV1/FVC, % | 512 | 0.81 (0.76–0.86) |
DLCO, % predicted | 394 | 47.0 (37.0–56.0) |
TLC, % predicted | 361 | 66.0 (57.0–74.0) |
CPI | 361 | 47.2 (40.5–55.3) |
GAP stage 1, (n, %) | 384 | 157 (40.9) |
Stage 2, (n, %) | 384 | 196 (51.0) |
Stage 3, (n, %) | 384 | 31 (8.1) |
Six-minute walk test* | ||
6MWD (m) | 375 | 430 (363–500) |
L-SpO2 (%) | 378 | 87.0 (82.0–91.0) |
Quality of life* | ||
K-BILD | 385 | 55.0 (48.0–62.0) |
Comorbidities (yes, n%) | 662 | 488 (73.7) |
CCI | 4 (3–5) | |
Anti-fibrotic therapy (yes, n %) | 662 | 360 (54.4) |
Death or transplant status (yes, n %) | 662 | 218 (32.9) |